Table 3.
Costs per patient (US$) | Linezolid (US$) | Vancomycin (US$) | Daptomycin (US$) |
---|---|---|---|
Total inpatient costs | $7,835 | $7,095 | $7,922 |
Inpatient drug costs | $626 | $119 | $713 |
Drug treatment | $554 | $47 | $659 |
Drug administration | $72 | $72 | $54 |
Inpatient medical costs | $7,209 | $6,976 | $7,209 |
Hospital days | $6,068 | $6,068 | $6,068 |
ID specialist | $232 | $232 | $232 |
Adverse event costsa | $435 | $201 | $435 |
Failure costs | $474 | $474 | $474 |
Total outpatient costs | $2,736 | $4,001 | $5,690 |
Outpatient drug costs | $2,086 | $634 | $2,766 |
Drug treatment | $2,075 | $487 | $2,698 |
Drug administration | $11 | $148 | $68 |
Outpatient medical costs | $650 | $3,367 | $2,924 |
Physician visit | $246 | $246 | $246 |
Laboratory work | $34 | $101 | $28 |
OPAT costb | $285 | $2,125 | $1,840 |
PICC line and complicationsb | $85 | $896 | $811 |
Total cost of treatment | $10,571 | $11,096 | $13,612 |
Total drug costs | $2,712 | $754 | $3,479 |
Total medical costs | $7,859 | $10,343 | $10,133 |
Notes: Costs may not tally due to rounding.
Adverse event costs are higher for linezolid and daptomycin arm because they are assigned the vancomycin adverse event costs from empiric treatment plus any linezolid/daptomycin adverse event costs. Vancomycin is only assigned adverse event costs once;
OPAT and PICC line costs are incurred in the linezolid arm through treatment failures and switching to other IV antibiotics.
Abbreviations: ID, infectious disease; OPAT, outpatient parenteral antibiotic therapy; PICC, peripherally inserted central catheter; IV, intravenous.